A team of Penn State researchers are interfacing chemical biology and nanotechnology to develop ultrasound-controlled nanomaterials that can provide on-demand, high precision delivery of proteins into human cells
IMAGE: JENNIFER MCCANN/PENN STATE
A new way to deliver therapeutic proteins inside the body uses an acoustically sensitive carrier to encapsulate the proteins and ultrasound to image and guide the package to the exact location required, according to Penn State researchers. Ultrasound then breaks the capsule, allowing the protein to enter the cell.
“When you expose the particle to ultrasound it opens a hole in the cell membrane that lasts for a couple of microseconds,” said Scott Medina, assistant professor of biomedical engineering, Penn State. “We can use this temporary opening to deliver antibodies, which are attractive therapeutic molecules in precision medicine that cannot otherwise get inside cells.”
These antibodies are emerging therapeutics for cancers, infectious diseases and rheumatoid arthritis, he said.
But getting the protein inside the nanoparticle carrier was not easy, which is why other researchers have had to resort to complicated and often poorly performing methods, such as attaching the cargo to the exterior of nanoparticles, resulting in inefficient protein release and off-target delivery.
The challenge with the new method was that the protein did not want to interact with the interior of the particle, which is made of a fluorous liquid, similar to liquid Teflon. Medina’s doctoral student, Janna Sloand, came up with a creative work around — a fluorous mask. These chemical masks have a counterbalance of polarity and fluorine content that allows the protein to interact with the fluorous liquid medium while maintaining the protein’s folded state and bioactivity.
“We had a lot of challenges developing this new method,” said Sloand, first author on the paper published recently in ACS Nano. “The most difficult was figuring out what kind of chemicals could mask the protein. That was definitely my eureka moment when I saw that it worked.”
In future work, the team will explore the use of their ultrasound-programmable material as a platform for image-guided delivery of therapeutic proteins and gene editing tools.
In related therapeutic applications, they are leveraging this technology to deliver antibodies that can alter abnormal signaling pathways in tumor cells to effectively ‘turn-off’ their malignant traits. In other work they are delivering gene editing tools, like CRISPR constructs, to enable ultrasound-controlled genome engineering of cells in complex 3D tissue microenvironments.
Importantly, these delivery applications can all be performed using ultrasound techniques already employed in hospitals, which they hope will enable the rapid translation of this technology for precision healthcare.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Novel mRNA delivery system produces a therapeutic protein that protects neurons from ischemiaon April 8, 2021 at 5:04 pm
A lack of oxygen to brain tissue--known as ischemia--leads to the death of neurons, which results in stroke. Despite considerable research, there are currently no treatments that successfully prevent ...
- Evaluation of carboxyfluorescein-labeled 7-methylguanine nucleotides as probes for studying cap-binding proteins by fluorescence anisotropyon April 8, 2021 at 12:57 pm
Fluorescence anisotropy (FA) is a powerful technique for the discovery of protein inhibitors in a high-throughput manner. In this study, we sought to develop new universal FA-based assays for the ...
- Outlook on the Biologic Therapeutic Drugs Global Market to 2025 - Growing Geriatric Population is Driving the Industryon April 7, 2021 at 6:30 am
Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report offers a detailed picture of the biologics market. This report highlights the current ...
- Recombinant Therapeutic Antibodies And Proteins Market Trends Predicts Huge Demand by 2027, Key Players – Novo Nordisk, Pfizer, Inc., Sanofi S.A.on April 7, 2021 at 4:16 am
The Recombinant Therapeutic Antibodies And Proteins Market is expected to grow at a CAGR of 7.1% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading ...
- Protein variant may have potential as target for glioblastomaon April 6, 2021 at 5:04 am
Inhibiting a novel protein variant within glioma stem cells may be a promising therapeutic approach to treat glioblastoma, according to a Northwestern Medicine study published in Nature Cell Biology.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Feed has no items.